Performance of ADMA ADMA Biologics | 105.6% in 12m
Compare ADMA with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare ADMA Biologics with its related Sector/Index XBI
Performance Duell ADMA vs XBI
TimeFrame | ADMA | XBI |
---|---|---|
1 Day | -2.08% | -0.02% |
1 Week | 6.62% | -0.33% |
1 Month | 22.7% | -6.54% |
3 Months | 46.0% | 4.44% |
6 Months | 86.4% | 28.65% |
12 Months | 105.6% | 27.48% |
YTD | 45.1% | 5.16% |
Rel. Perf. 1m | 2.60 | |
Rel. Perf. 3m | 2.28 | |
Rel. Perf. 6m | 3.64 | |
Rel. Perf. 12m | 4.73 |
Is ADMA Biologics a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, ADMA Biologics (NASDAQ:ADMA) is currently (March 2024)
ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 3.98 and therefor a somewhat positive outlook according to fundamental data.
Based on ValueRays Technical Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADMA as of March 2024 is 6.60. This means that ADMA is currently overvalued and has a potential downside of 0%.
Based on ValueRays Technical Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADMA as of March 2024 is 6.60. This means that ADMA is currently overvalued and has a potential downside of 0%.
Is ADMA a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
Values above 0%: ADMA is performing better - Values below 0%: ADMA is underperforming
Compare ADMA with Broad Market Indices
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 6.45% | 19.04% | 63.50% | 71.47% |
US NASDAQ 100 | QQQ | 7.04% | 20.54% | 61.94% | 60.07% |
US Dow Jones Industrial 30 | DIA | 6.62% | 20.34% | 67.17% | 80.39% |
German DAX 40 | DBXD | 4.85% | 17.60% | 65.86% | 84.16% |
UK FTSE 100 | ISFU | 5.86% | 17.75% | 76.27% | 92.62% |
Shanghai Shenzhen CSI 300 | CSI 300 | 8.50% | 20.86% | 90.87% | 121.30% |
Hongkong Hang Seng | HSI | 10.16% | 27.40% | 92.54% | 126.16% |
Japan Nikkei 225 | EXX7 | 7.16% | 19.13% | 64.58% | 77.30% |
India NIFTY 50 | INDA | 4.52% | 21.64% | 69.85% | 71.01% |
Brasil Bovespa | EWZ | 7.02% | 25.47% | 76.23% | 76.68% |
ADMA ADMA Biologics vs. Sectors
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 6.61% | 18.59% | 61.96% | 58.09% |
Consumer Discretionary | XLY | 6.86% | 22.07% | 71.15% | 74.83% |
Consumer Staples | XLP | 6.16% | 19.53% | 74.13% | 98.67% |
Energy | XLE | 4.67% | 11.65% | 82.28% | 84.69% |
Financial | XLF | 6.09% | 17.93% | 59.54% | 69.12% |
Health Care | XLV | 5.18% | 21.14% | 71.63% | 87.42% |
Industrial | XLI | 6.37% | 17.94% | 61.79% | 75.21% |
Materials | XLB | 5.59% | 15.40% | 67.13% | 83.68% |
Real Estate | XLRE | 5.47% | 20.11% | 67.97% | 89.53% |
Technology | XLK | 7.37% | 20.77% | 58.46% | 59.95% |
Utilities | XLU | 3.67% | 16.06% | 72.87% | 102.64% |
Aerospace & Defense | XAR | 6.07% | 20.02% | 60.34% | 82.27% |
Biotech | XBI | 6.95% | 29.22% | 57.79% | 78.13% |
Homebuilder | XHB | 6.13% | 13.38% | 41.17% | 34.29% |
Retail | XRT | 5.53% | 18.48% | 54.88% | 74.12% |
Does ADMA Biologics outperform its market, is ADMA a Sector Leader?
Yes, over the last 12 months ADMA Biologics (ADMA) made 105.61%, while its related Sector, the SPDR S&P Biotech (XBI) made 27.48%.
Over the last 3 months ADMA made 46.02%, while XBI made 4.44%.
Yes, over the last 12 months ADMA Biologics (ADMA) made 105.61%, while its related Sector, the SPDR S&P Biotech (XBI) made 27.48%.
Over the last 3 months ADMA made 46.02%, while XBI made 4.44%.
Period | ADMA | XBI | S&P 500 |
---|---|---|---|
1 Month | 22.68% | -6.54% | 3.64% |
3 Months | 46.02% | 4.44% | 10.07% |
12 Months | 105.61% | 27.48% | 34.14% |